Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study

Christopher Kruse, Sabrina Kretschmer, Anna Lipinski, Malte Verheyen, David Mengel, Monika Balzer-Geldsetzer, Stefan Lorenzl, Carmen Richinger, Christian Schmotz, Lars Tönges, Dirk Woitalla, Stephan Klebe, Anette Schrag and Richard Dodel ()
Additional contact information
Christopher Kruse: University of Duisburg-Essen
Sabrina Kretschmer: University of Duisburg-Essen
Anna Lipinski: University of Duisburg-Essen
Malte Verheyen: University of Duisburg-Essen
David Mengel: University of Tübingen
Monika Balzer-Geldsetzer: University of Duisburg-Essen
Stefan Lorenzl: Department of Neurology, Ludwig-Maximilians University
Carmen Richinger: Paracelsus Medical University
Christian Schmotz: Paracelsus Medical University
Lars Tönges: Ruhr-University
Dirk Woitalla: St. Josef-Krankenhaus Kupferdreh
Stephan Klebe: Essen University Hospital
Anette Schrag: King’s College
Richard Dodel: University of Duisburg-Essen

PharmacoEconomics, 2021, vol. 39, issue 5, No 10, 615 pages

Abstract: Abstract Objective The Care of Late-Stage Parkinsonism (CLaSP) study aimed to collect qualitative and standardized patient data in six European countries (France, Germany, Netherlands, Portugal, UK, Sweden) to enable a detailed evaluation of the underexplored late stages of the disease (Hoehn and Yahr stage > 3) using clinical, neuropsychological, behavioral, and health economic data. The aim of this substudy was to provide a health economic evaluation for the German healthcare system. Methods In Germany, 228 patients were included in the study. Costs were calculated from a societal perspective for a 3-month period. Univariate analyses were performed to identify cost-driving predictors. Total and direct costs were analyzed using a generalized linear model with a γ-distributed dependent variable and log link function. Indirect costs were analyzed using a binomial generalized linear model with probit link function. Results The mean costs for the 3-month period were approximately €20,000. Informal care costs and hospitalization are approximately €11,000 and €5000. Direct costs amounted to 89% of the total costs, and the share of indirect costs was 11%. Independent predictors of total costs were the duration of the disease and age. The duration of the disease was the main independent predictor of direct costs, whereas age was an independent predictor of indirect costs. Discussion Costs in the late stage of the disease are considerably higher than those found in earlier stages. Compared to the latter, the mean number of days in hospital and the need for care is increasing. Informal caregivers provide most of the care. Clinical Trial Registration The protocol was registered at ClinicalTrials.gov as NCT02333175 on 7 January, 2015.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-021-01011-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:39:y:2021:i:5:d:10.1007_s40273-021-01011-y

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-021-01011-y

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().